Catalyst Wire Dossier Catalyst Wire Dossier

iGlarLixi (insulin glargine/lixisenatide) fixed-ratio combination

insulin glargine / lixisenatide · Sanofi
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for iGlarLixi (insulin glargine/lixisenatide) fixed-ratio combination, covering 2017-02-10 to 2017-02-10. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM [Phase 3]

See pricing